Jump to navigation Jump to search
|Chemical and physical data|
|Molar mass||144602.93 g·mol−1|
|(what is this?)|
Robatumumab (proposed INN; also known as SCH 717454 and MK-7454) is a monoclonal antibody and an antineoplastic by Merck and Schering-Plough. It binds to CD221, the insulin-like growth factor 1 receptor.
- "robatumumab", p. 337 in: Quality Assurance and Safety of Medicines (2008). Encrenaz C (ed.). "Proposed International Nonproprietary Names: List 100" (PDF). WHO Drug Information. 22 (4): 311–67.
- Anderson PM, Bielack SS, Gorlick RG, Skubitz K, Daw NC, Herzog CE, et al. (October 2016). "A phase II study of clinical activity of SCH 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcoma". Pediatric Blood & Cancer. 63 (10): 1761–70. doi:10.1002/pbc.26087. PMC 5129487. PMID 27362300.
- Clinical trial number NCT00551213 for "A Study to Determine the Activity of Robatumumab (SCH 717454, MK-7454) in Participants With Relapsed or Recurrent Colorectal Cancer (P04721, MK-7454-003)" at ClinicalTrials.gov
- "Robatumumab". Adis Insight. Springer Nature Switzerland AG.
|This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.|
|This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.|